Alberta Health Services
🇨🇦Canada
- Country
- 🇨🇦Canada
- Ownership
- Private
- Established
- 2009-04-01
- Employees
- 10K
- Market Cap
- -
Evaluation of Clinical Significance of Circulating Markers in Breast Cancer Patients Undergoing Herceptin Therapy
- Conditions
- Breast Cancer
- First Posted Date
- 2007-09-17
- Last Posted Date
- 2013-01-28
- Lead Sponsor
- Alberta Health services
- Target Recruit Count
- 60
- Registration Number
- NCT00530569
- Locations
- 🇨🇦
Tom Baker Cancer Centre, Calgary, Alberta, Canada
Minimized Time to Beam in Patients With High Grade Gliomas
Not Applicable
Withdrawn
- Conditions
- High Grade Glioma
- First Posted Date
- 2007-05-04
- Last Posted Date
- 2011-09-22
- Lead Sponsor
- Alberta Health services
- Registration Number
- NCT00469534
Study of N-Acetylcysteine (NAC) and Continuous Renal Replacement Therapy (CRRT) for the Treatment of Rhabdomyolysis
Phase 2
Completed
- Conditions
- Rhabdomyolysis
- Interventions
- Other: N-Acetylcystine and Non CRRTOther: Placebo and CRRTOther: Placebo and Non CRRT
- First Posted Date
- 2006-10-25
- Last Posted Date
- 2012-03-05
- Lead Sponsor
- Royal Alexandra Hospital
- Target Recruit Count
- 3
- Registration Number
- NCT00391911
- Locations
- 🇨🇦
Royal Alexandra Hospital, Edmonton, Alberta, Canada
🇸🇦King Fahad National Guard Hospital, Riyadh, Saudi Arabia
Safety of Darbepoetin Alfa Treatment in Patients With Severe Traumatic Brain Injury
Phase 2
Completed
- Conditions
- Traumatic Brain Injury
- Interventions
- Drug: DarbeopoetinDrug: Normal Saline (Placebo)
- First Posted Date
- 2006-09-13
- Last Posted Date
- 2012-03-05
- Lead Sponsor
- Royal Alexandra Hospital
- Target Recruit Count
- 10
- Registration Number
- NCT00375869
- Locations
- 🇨🇦
Royal Alexandra Hospital, Edmonton, Alberta, Canada
🇨🇦University of Alberta Hospital, Edmonton, Alberta, Canada
A Study of Conventional 3D Radiation vs. Intensity-Modulated Radiation in Squamous Cell Cancer of the Head and Neck
Phase 2
Withdrawn
- Conditions
- Head and Neck NeoplasmsSquamous Cell Cancer
- First Posted Date
- 2006-08-15
- Last Posted Date
- 2012-01-19
- Lead Sponsor
- Alberta Health services
- Registration Number
- NCT00363441
Frequency of Circulating Tumour Cells in Stage II and Stage III Colon Cancer Patients
Completed
- Conditions
- Colon Cancer
- First Posted Date
- 2006-07-13
- Last Posted Date
- 2011-04-18
- Lead Sponsor
- Alberta Health services
- Target Recruit Count
- 30
- Registration Number
- NCT00351572
- Locations
- 🇨🇦
Cross Cancer Institute, Edmonton, Alberta, Canada
Sublingual Methadone for the Management of Cancer-related Procedure Pain in Inpatients
Phase 2
Terminated
- Conditions
- CancerPain
- First Posted Date
- 2006-07-13
- Last Posted Date
- 2012-01-19
- Lead Sponsor
- Alberta Health services
- Target Recruit Count
- 60
- Registration Number
- NCT00351637
- Locations
- 🇨🇦
Tom Baker Cancer Center, Calgary, Alberta, Canada
Orexigenic Therapy With Delta-9-tetrahydrocannabinol in Advanced Cancer Patients With Chemosensory Abnormalities - a Pilot Study
Phase 2
Completed
- Conditions
- CancerAnorexiaTaste DisordersOlfactory Disorders
- Interventions
- Other: Placebo
- First Posted Date
- 2006-04-21
- Last Posted Date
- 2010-02-09
- Lead Sponsor
- Alberta Health services
- Target Recruit Count
- 80
- Registration Number
- NCT00316563
- Locations
- 🇨🇦
Cross Cancer Institute, Edmonton, Alberta, Canada
🇨🇦Royal Victoria Hospital, Montreal, Quebec, Canada
Review of Palliative Radiotherapy in the Management of Advanced Head and Neck Cancer
Completed
- Conditions
- Head and Neck Cancer
- First Posted Date
- 2006-01-24
- Last Posted Date
- 2013-01-28
- Lead Sponsor
- Alberta Health services
- Target Recruit Count
- 100
- Registration Number
- NCT00280891
- Locations
- 🇨🇦
Tom Baker Cancer Centre, Calgary, Alberta, Canada
Review of Multimodality Management of Anaplastic Thyroid Cancer
Completed
- Conditions
- Anaplastic Thyroid Cancer
- First Posted Date
- 2006-01-24
- Last Posted Date
- 2011-11-21
- Lead Sponsor
- Alberta Health services
- Target Recruit Count
- 5
- Registration Number
- NCT00280852
- Locations
- 🇨🇦
Tom Baker Cancer Centre, Calgary, Alberta, Canada